Security
POMDOCTOR LIMITED American Depositary Shares · POM
POMNASDAQotherCurrentCIK 1877971Updated Oct 12, 2026
POM price & chart
Loading TradingView…
NASDAQ:POM on TradingView ↗About the company
We are a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market measured by the number of contracted doctors in 2022, according to Frost & Sullivan. As of December 31, 2023 and 2024, the cumulative number of contracted doctors stabilized at over 212,800, while the transacting patients increased from 654,817 as of December 31, 2023 to 699,338 as of December 31, 2024. As of December 31, 2024, our contracted doctors issued approximately 3.13 million prescriptions.
In the news
POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change ↗
POM DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - POM ↗
POM DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - POM ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 15,380,509Source | 46,227,586Source |
| Property, Plant and Equipment, NetUSD | 178,257Source | 461,362Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,369,974Source | 1,094,178Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,636,954Source | 8,374,608Source |
| Inventory, NetUSD | 1,184,045Source | 9,165,973Source |
| Assets, CurrentUSD | 15,010,029Source | 37,497,413Source |
| Other Assets, NoncurrentUSD | 192,223Source | 831,132Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 84,205,017Source | 545,908,548Source |
| Stockholders’ equity: | ||
| Additional Paid in CapitalUSD | 289,394,627Source | — |
| Retained Earnings (Accumulated Deficit)USD | -354,063,090Source | -2,263,419,477Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -250,598Source | -5,231Source |
| Stockholders' Equity Attributable to ParentUSD | -64,917,028Source | -2,263,421,920Source |
| Liabilities and EquityUSD | 15,380,509Source | 46,227,586Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 31,197,632Source | 179,145,471Source |
| Operating Lease, Liability, CurrentUSD | 220,932Source | 1,388,863Source |
| Accounts Payable, CurrentUSD | 6,408,303Source | 25,320,486Source |
| Operating Lease, Liability, NoncurrentUSD | 185,112Source | 1,672,218Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -3,907,480Source | 18,166Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 2,085,008Source | 9,712,966Source |
| Long-term DebtUSD | 11,700,687Source | — |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountCNY | — | 168,671,234Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -18,723,015Source | -37,365,434Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,348,555Source | — |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 1,444,193Source | -20,309,367Source |
| Increase (Decrease) in InventoriesUSD | 142,684Source | -3,033,987Source |
| Increase (Decrease) in Accounts PayableUSD | 2,787,521Source | -16,254,687Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -21,232,309Source | -16,130,880Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -229,906Source | -33,373Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 144,107Source | 37,773Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 22,011,227Source | 17,016,080Source |
| Repayments of Long-term DebtUSD | 17,088Source | 391,667Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 275,796Source | 846,596Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 386,610Source | 2,744,793Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 2,348,555Source | — |
| DepreciationUSD | 21,351Source | 134,510Source |
| Gain (Loss) on Disposition of Property Plant EquipmentCNY | — | 3,893Source |
| General and Administrative ExpenseUSD | 8,541,184Source | 11,878,335Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -18,723,015Source | -37,365,434Source |
| Income Tax Expense (Benefit)USD | 54Source | — |
| Inventory Write-downUSD | 269,355Source | 494,459Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -217Source | 25,878Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -30,398,409Source | -143,360,926Source |
| Nonoperating Income (Expense)USD | -1,758,407Source | -11,574,154Source |
| Operating ExpensesUSD | 24,440,796Source | 73,485,333Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 57,187,079Source | 342,557,920Source |
| Cost of Goods and Services Sold | — | — |
| Operating Income (Loss)USD | -16,964,554Source | -25,791,280Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -18,722,961Source | -37,365,434Source |
| Income Tax Expense (Benefit)USD | 54Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -217Source | 25,878Source |
| Earnings Per Share, BasicUSD per share | -3.14Source | -22.72Source |
| Earnings Per Share, DilutedUSD per share | -3.14Source | -22.72Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 9,680,622Source | 6,310,198Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 9,680,622Source | 6,310,198Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 8,541,184Source | 11,878,335Source |
| Gross ProfitUSD | 7,476,242Source | 47,694,053Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -18,723,015Source | -37,365,434Source |
| Interest Expense, DebtUSD | 563,464Source | 3,632,425Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -30,398,409Source | -143,360,926Source |
| Nonoperating Income (Expense)USD | -1,758,407Source | -11,574,154Source |
| Operating ExpensesUSD | 24,440,796Source | 73,485,333Source |
| Research and Development ExpenseUSD | 1,839,621Source | 3,002,040Source |
| Selling and Marketing ExpenseUSD | 13,758,477Source | 56,366,433Source |
Offerings
Registration 333-285771
- Gross proceeds
- 20000016.0
- Net proceeds
- 18600015.0
- Deal price
- 4.0
- Shares
- 5000004
- Offering price
- $4.00
- Ticker
- POM
Filing attachments
ea030814601ex99-1.htm · 6-K · 2026-10-09
Exhibit 99.1 POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination GUANGZHOU, China, October 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq…
Read attachment ↗ea030698701ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization GUANGZHOU, China, September 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI-enabled chronic disease management ecosystem, including further optimization of its propr…
Read attachment ↗ea030638801ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 POMDOCTOR LIMITED INDEX TO FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as of December 31, 2025 and June 30, 2026 F-2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2025 and 2026 F-6 Unaudited Condensed Consolidated Statements of Changes in Deficit for the Six Months Ended June 30, 2025 and 2026 F-7 Unaudited Cond…
Read attachment ↗ea030638801ex99-2.htm · 6-K · 2026-09-29
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF POMDOCTOR LIMITED A. Operating Results Key Factors Affecting Our Results of Operations General Factors Affecting Our Results of Operations Our results of operations and financial condition are affected by the general factors driving China’s Internet industry in China, which include China’s overall economic growth and level of per capital disposable income, growth of mobile Internet usage a…
Read attachment ↗ea030654201ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 POMDOCTOR LIMITED Highlights Differentiated “Hardware + AI + Payment” Healthcare Infrastructure Model GUANGZHOU, China, September 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its differentiated “hardware + AI + payment” infrastructure model. The Company believes this integrated approach distinguishes it from traditional internet healthcar…
Read attachment ↗ea030509401ex99-1.htm · 6-K · 2026-09-10
Exhibit 99.1 POMDOCTOR LIMITED to Participate in H.C. Wainwright’s 28th Annual Global Investment Conference Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Confer…
Read attachment ↗